Brise Pharmaceuticals disclosed a licensing agreement with AbbVie covering two preclinical migraine programs, with potential consideration up to $757 million across development, regulatory and commercial milestones. Brise said the deal, signed in 2024 without immediate public disclosure, does not include an upfront payment and assigns Brise to discovery while AbbVie leads global development and commercialization. Brise, founded in 2021, pairs small molecules with targeted antibodies and highlighted BR005, an oral candidate in Phase II/III for acute migraine in the NCT07792681 study. The announced partnership adds a second discovery-to-clinic path financed by a large pharma partner. The disclosure matters for migraine R&D as late-stage competition intensifies around oral and next-generation acute therapies, especially as developers differentiate on mechanism and delivery.